La ferroptose, une nouvelle forme de mort cellulaire applicable au traitement médical des cancers

Lachaier, Emma; Louandre, Christophe; Ezzoukhry, Zakaria; Godin, C.; Mazière, Jean‐Claude; Chauffert, Bruno; Galmiche, Antoine

doi:10.1051/medsci/20143008016

Cited by 12 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various therapeutics are described for a targeted induction of ferroptosis in castration-resistant PCa, already. These include Flubendazole [29], Sulfasalazine [30,31], Sorafenib [32], Erastin, and RSL-3 [33]. Complementary, we detected an average induction of xCT expression in PCa with increasing Gleason score at RNA level and also at protein level.…”

Section: Discussionsupporting

confidence: 54%

xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis

Wilhelm,

Wiesehöfer,

Dankert

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Prostate cancer is the second most common type of cancer in male worldwide. Stromal-epithelial interaction is thought to have a major impact on cancer development and progression. Interaction via soluble factors previously revealed a reduction in the expression of xCT and AL122023.1 in prostate carcinoma cells LNCaP after seven days of co-culture with stromal primary p21 cells. Furthermore, xCT is known to be a putative target for miR-26a, miR-30d and miR-30e which in turn potentially interact with the lncRNA AL122023.1. Methods We validated the repression of xCT and AL122023.1 at RNA level by quantitative real-time PCR and at protein level by Western Blotting. The lncRNA-miRNA-interaction was analyzed by luciferase reporter assays whereas the localization and distribution of xCT in prostate tissue of different developmental stages was evaluated by immunostaining. Results The interaction between AL122023.1 and miR-26a/-30d/-30e was verified and further investigated at protein level regarding xCT. An indirect inhibitory effect of AL122023.1 on the xCT expression could be shown, but miR-26a/-30d/-30e caused no inhibition. Moreover, immunostaining displayed a precise xCT expression in neuroendocrine cells ranging from fetal, healthy juvenile and adult prostate tissue to benign prostatic hyperplasia and finally advanced prostate cancer. Conclusion This study explores the relevance and function of xCT and AL122023.1 in the prostate and exposes xCT as a potential marker or therapeutic target in high-risk prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 54%

xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis

Wilhelm,

Wiesehöfer,

Dankert

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The inhibition of XAV939 in the proliferation and migration of lung adenocarcinoma cells was determined by modulating certain biological pathways, including that of WNT (49). Ferroptosis, a type of programmed cell death dependent on iron, inhibits tumor growth and increases drug resistance (50,51). A previous study revealed that the inhibition of ferroptosis influences lung cancer progression (52).…”

Section: Discussionmentioning

confidence: 99%

RNA sequencing uncovers the key long non‑coding RNAs and potential molecular mechanism contributing to XAV939‑mediated inhibition of non‑small cell lung cancer

Han

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

The present study aimed to reveal the key long non-coding RNAs (lncRNAs) and the potential molecular mechanisms of XAV939 treatment in non-small cell lung cancer (NSCLC). The NSCLC cell line, NCI-H1299, was cultured with 10 µM XAV939 for 12 h, and NCI-H1299 cells without XAV939 treatment were used as controls. Following RNA isolation from the two groups, RNA-sequencing was performed to detect transcript expression levels, and differentially-expressed lncRNAs (DE-lncRNAs) and DE-genes (DEGs) were identified between groups and analyzed for their functions and associated pathways. The potential associations between proteins encoded by DEGs were revealed via a protein-protein interaction (PPI) network. Subsequently, the microRNA (miRNA/miR)-mRNA, lncRNA-miRNA and lncRNA-mRNA interactions were explored, followed by competing endogenous RNA (ceRNA) network construction. A total of 396 DEGs and 224 DE-lncRNAs were identified between the XAV939 and control groups. These lncRNAs were mainly enriched in pathways such as ‘ferroptosis’ [DEG, solute carrier family 7 member 11 ( SLC7A11 )]. The PPI network consisted of 97 nodes and 112 interactions. Furthermore, a total of 10 noteworthy lncRNAs were revealed in the DE-lncRNA-DEG interaction. Finally, the lncRNA-miRNA-mRNA regulatory association, including MIR503 host gene ( MIR503HG )- miR1273c -SRY-box 4 ( SOX4 ), was explored in the current ceRNA network. The downregulation of lncRNA MIR503HG induced by XAV939 may serve an important role in NSCLC suppression via sponging miR-1273c and regulating SOX4 expression. Furthermore, the downregulation of SLC7A11 induced by XAV939 may also inhibit the development of NSCLC via the ferroptosis pathway.

show abstract

“…Plusieurs acteurs des voies de biosynthèse des lipides (AMPK [AMP-activated protein kinase] [5], SCD1 [stearoyl-CoA desaturase 1] [6]) et des glycérophospholipides (lysophosholipide acyltransferase 3, acyl-CoA synthetase long chain family member 3 et 4 [7]), ainsi que de leur stockage (TPD52 [tumor protein D52], et lipophagie [8]), modulent la sensibilité des cellules à la ferroptose en contrôlant la composition de leurs membranes en acides gras mono-et polyinsaturés. Le peroxysome s'est également imposé récemment comme un composant majeur de la susceptibilité cellulaire à la ferroptose, du fait de son rôle dans la formation des plasmalogènes, des éthers lipidiques ou étherlipides 1 , En 2014, E. Lachaier et al avaient proposé dans médecine/sciences une Synthèse sur la ferroptose et le cancer [1] (➜). Depuis, des recherches intenses ont précisé et complexifié les mécanismes mis en jeu dans ce processus, révélant de nouveaux acteurs essentiels.…”

Section: Les Acides Gras Polyinsaturésunclassified

Ferroptose et cancer

et al. 2021

View full text Add to dashboard Cite

La ferroptose est un processus conduisant à la mort de la cellule avec, pour évènement final, l’accumulation létale de lipides peroxydés. Le fer libre intracellulaire est au centre des réactions entraînant la formation de ces lipides peroxydés. Un système antioxydant dédié à la détoxification de ces lipides permet de prévenir la mort cellulaire. Le processus de ferroptose est impliqué dans un grand nombre de maladies, notamment dans la pathogénie des maladies neurodégénératives et infectieuses et du cancer. Nous présentons dans cette revue les principaux acteurs cellulaires qui contrôlent la ferroptose et proposons une synthèse des données actuelles impliquant ce processus dans le cancer.

show abstract

La ferroptose, une nouvelle forme de mort cellulaire applicable au traitement médical des cancers

Cited by 12 publications

References 24 publications

xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis

xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis

RNA sequencing uncovers the key long non‑coding RNAs and potential molecular mechanism contributing to XAV939‑mediated inhibition of non‑small cell lung cancer

Ferroptose et cancer

Contact Info

Product

Resources

About